TOIIW (The Oncology Institute) Growth Rank: 9 (As of Jul. 17, 2026) — 80% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TOIIW The Oncology Institute Inc TOIIW
60 GF Score
Price $0.07
! 4 Warning Signs
View Full Analysis

What is The Oncology Institute Growth Rank?

The Oncology Institute TOIIW +26.91% 60 Growth Rank is 9 as of Jul. 17, 2026, which is 80% above its 10-year median of 5.00. GuruFocus rates TOIIW with a GF Score™ of 60/100. The stock has 4 warning signs investors should review.

The Oncology Institute has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

The Oncology Institute Growth Rank Related Terms

TOIIW vs CYH, SRTA, CCRN: Growth Rank Comparison

For the Medical Care Facilities subindustry, The Oncology Institute's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Oncology Institute Growth Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's Growth Rank distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's Growth Rank falls into.


TOIIW
60GF Score
The Oncology Institute Inc TOIIW
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
The Oncology Institute (TOIIW) has a Growth Rank of 9 as of Jul. 17, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on The Oncology Institute and its competitors. This is 80% above median its historical median of 5.00. Over the past decade, The Oncology Institute's Growth Rank has ranged from 2.00 to 9.00.
Is The Oncology Institute's Growth Rank too high?
The Oncology Institute's current Growth Rank of 9 is 80% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 9.00. Overall, The Oncology Institute has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does The Oncology Institute's Growth Rank compare to CYH and SRTA?
The Oncology Institute's Growth Rank of 9 can be compared against companies in the Healthcare Providers & Services industry. Historically, The Oncology Institute's own Growth Rank has ranged from 2.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Healthcare Providers & Services company?
A good Growth Rank depends on the Healthcare Providers & Services industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on The Oncology Institute and its competitors. The Oncology Institute's current Growth Rank is 9, which is 80% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Oncology Institute stock overvalued right now?
The Oncology Institute (TOIIW) has a current Growth Rank of 9. The current Growth Rank is 9, which is 80% above median its 10-year median of 5.00. The Oncology Institute's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For The Oncology Institute (TOIIW), the current Growth Rank is 9 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Oncology Institute Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
60GF Score

Get the complete analysis for TOIIW

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price